Abstract P5-08-20: Association between quantitative mammographic density and breast cancer subtypes among Chinese breast cancer patients

2020 ◽  
Author(s):  
Xiaohong R Yang ◽  
Yuan Tian ◽  
Jennifer Guida ◽  
Hela Koka ◽  
Ariane Chan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Mammographic Density ◽  
Breast Cancer Subtypes ◽  
Breast Cancer Patients ◽  
Cancer Subtypes

scholarly journals Clinical Significance of Annexin A2 Expression in Breast Cancer Patients

Cancers ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 2
Author(s):  
Lee D. Gibbs ◽  
Kelsey Mansheim ◽  
Sayantan Maji ◽  
Rajesh Nandy ◽  
Cheryl M. Lewis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Significance ◽  
Cell Lines ◽  
Breast Cancer Subtypes ◽  
Enzyme Linked Immunosorbent Assay ◽  
Breast Cancer Patients ◽  
Serum Samples ◽  
Cancer Subtypes ◽  
Tumor Tissues

Increasing evidence suggests that AnxA2 contributes to invasion and metastasis of breast cancer. However, the clinical significance of AnxA2 expression in breast cancer has not been reported. The expression of AnxA2 in cell lines, tumor tissues, and serum samples of breast cancer patients were analyzed by immunoblotting, immunohistochemistry, and enzyme-linked immunosorbent assay, respectively. We found that AnxA2 was significantly upregulated in tumor tissues and serum samples of breast cancer patients compared with normal controls. The high expression of serum AnxA2 was significantly associated with tumor grades and poor survival of the breast cancer patients. Based on molecular subtypes, AnxA2 expression was significantly elevated in tumor tissues and serum samples of triple-negative breast cancer (TNBC) patients compared with other breast cancer subtypes. Our analyses on breast cancer cell lines demonstrated that secretion of AnxA2 is associated with its tyrosine 23 (Tyr23) phosphorylation in cells. The expression of non-phosphomimetic mutant of AnxA2 in HCC1395 cells inhibits its secretion from cells compared to wild-type AnxA2, which further suggest that Tyr23 phosphorylation is a critical step for AnxA2 secretion from TNBC cells. Our analysis of AnxA2 phosphorylation in clinical samples further confirmed that the phosphorylation of AnxA2 at Tyr23 was high in tumor tissues of TNBC patients compared to matched adjacent non-tumorigenic breast tissues. Furthermore, we observed that the diagnostic value of serum AnxA2 was significantly high in TNBC compared with other breast cancer subtypes. These findings suggest that serum AnxA2 concentration could be a potential diagnostic biomarker for TNBC patients.

scholarly journals PIWI-Like 1 and PIWI-Like 2 Expression in Breast Cancer

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2742
Author(s):  
Ramona Erber ◽  
Julia Meyer ◽  
Helge Taubert ◽  
Peter A. Fasching ◽  
Sven Wach ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Disease Free Survival ◽  
Breast Cancer Subtypes ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Cancer Subtypes ◽  
Prognostic Effect ◽  
Enhanced Expression ◽  
Disease Free

PIWI-like 1 and PIWI-like 2 play a role in stem cell self-renewal, and enhanced expression has been reported for several tumor entities. However, few studies have investigated PIWI-like 1 and PIWI-like 2 expressions in breast cancer subtypes regarding prognosis. Therefore, we examined protein expression in a large consecutive cohort of breast cancer patients and correlated it to breast cancer subtypes and survival outcome. PIWI-like 1 and PIWI-like 2 expressions were evaluated using immunohistochemistry in a cohort of 894 breast cancer patients, of whom 363 were eligible for further analysis. Percentage and intensity of stained tumor cells were analyzed and an immunoreactive score (IRS) was calculated. The interaction of PIWI-like 1 and PIWI-like 2 showed a prognostic effect on survival. For the combination of high PIWI-like 1 and low PIWI-like 2 expressions, adjusted hazard ratios (HRs) were significantly higher with regard to overall survival (OS) (HR 2.92; 95% confidence interval (CI) 1.24, 6.90), disease-free survival (DFS) (HR 3.27; 95% CI 1.48, 7.20), and distant disease-free survival (DDFS) (HR 7.64; 95% CI 2.35, 24.82). Both proteins were significantly associated with molecular-like and PAM50 subgroups. Combining high PIWI-like 1 and low PIWI-like 2 expressions predicted poorer prognosis and both markers were associated with aggressive molecular subtypes.

scholarly journals Quantitative Mammographic Density Measurements and Molecular Subtypes in Chinese Women with Breast Cancer

2020 ◽  
Author(s):  
Yuan Tian ◽  
Jennifer L Guida ◽  
Hela Koka ◽  
Er-Ni Li ◽  
Bin Zhu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Mammographic Density ◽  
Chinese Women ◽  
Statistical Tests ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Luminal A ◽  
Cancer Subtypes ◽  
Luminal B

Abstract Background Studies investigating associations between mammographic density (MD) and breast cancer subtypes have generated mixed results. We previously showed that having extremely dense breasts was associated with the HER2-enriched subtype in Chinese breast cancer patients. Methods In this study, we re-evaluated the MD-subtype association in 1,549 Chinese breast cancer patients, using VolparaDensity software to obtain quantitative MD measures. All statistical tests were two-sided. Results Compared to women with luminal A tumors, women with luminal B/HER2- (odds ratio [OR]=1.20, 95% confidence interval [CI]: 1.04-1.38, p = 0.01), luminal B/HER2 + (OR = 1.22, 95% CI: 1.03-1.46, p = 0.03), and HER2-enriched tumors (OR = 1.30, 95% CI: 1.06-1.59, p = 0.01) had higher fibroglandular dense volume. These associations were stronger in patients with smaller tumors (<2cm). In contrast, the triple negative subtype was associated with lower non-dense volume (OR = 0.82, 95% CI: 0.68-0.99, p = 0.04), and the association was only seen among older women (>50 years old). Conclusion Although biological mechanisms remain to be investigated, the associations for the HER2-enriched and luminal B subtypes with increasing MD may partially explain the higher prevalence of luminal B and HER2+ breast cancers previously reported in Asian women.

scholarly journals Breast Cancer Subtypes and Outcome in Elderly Breast Cancer Patients Aged 70 Years and Older

2012 ◽  
Vol 23 ◽  
pp. ix100
Author(s):  
R. Königsberg ◽  
G. Pfeiler ◽  
N. Hammerschmid ◽  
T. Klement ◽  
A. Brunner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Subtypes ◽  
Breast Cancer Patients ◽  
Cancer Subtypes

c-kit: Identification of co-regulated genes by gene expression profiling and clinical relevance of two breast cancer subtypes with stem cell like features

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 622-622 ◽  
Author(s):  
A. Rody ◽  
U. Holtrich ◽  
V. Müller ◽  
R. Gaetje ◽  
R. Diallo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Stem Cell ◽  
Gene Expression Profiling ◽  
Cancer Patients ◽  
Expression Profiling ◽  
Breast Cancer Subtypes ◽  
Expression Data ◽  
Breast Cancer Patients ◽  
Cancer Subtypes

622 Background: Expression of the proto-oncogene c-kit has been found in malignant tissue including a subset of breast cancers. c-Kit is also expressed in normal breast tissue and several authors found a loss of c-kit expression in breast carcinoma suggesting it might be involved in the growth control of mammary epithelium. Until now, only a few markers were described to be co-regulated with c-kit. To elucidate the possible role of c-kit in malignant transformation, we analyzed gene expression data of breast cancer patients. Methods: Tumor tissue of n=171 breast cancer patients were analyzed by gene expression profiling using Affymetrix Hg U133 Arrays (22,500 genes) and bioinformatic analyses. Tumor samples with high stromal and low epithelial cell content by gene expression profiling were excluded for further analysis. Validation was performed with n=100 independent samples. Results: A total of 10.5% of the tumors showed strong c-kit expression (2.5 fold above median). A careful dissection of global expression data revealed strong correlations of c-kit with the expression of a large cluster of genes containing several for whom c-kit coexpression was already described (HER1, CK-5/-17, PDGFR) as well as several members of the wnt signalling pathway, providing a possible novel link to mammary epithelial differentiation. Analysis of n=171 breast cancer samples according to this gene set allows the identification of putative “stem cell like” tumors (SCL) characterized by expression of several known stem cell markers. Surprisingly, a tight link of ER status and proliferation is restricted only to these SCL tumors but lost among non-SCL tumors. The clinical implications of our findings will be presented. Conclusions: For the first time these data bring together the description of two breast cancer subtypes identified by gene expression profiling with the actual stem cell model of the development of breast cancer. No significant financial relationships to disclose.

scholarly journals The Relationship of Breast Cancer Subtypes with the Event of Metastasis in Dr. M. Djamil Hospital Padang

2021 ◽  
Vol 5 (4) ◽  
pp. 1199-1205
Author(s):  
Ahmad Fakhrozi Helmi ◽  
Daan Khambri ◽  
Rony Rustam
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Odds Ratio ◽  
Breast Cancer Subtypes ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Luminal A ◽  
Cancer Subtypes ◽  
Luminal B ◽  
The Relationship

Background: One of the high mortality rates from breast cancer is related to the incidence of metastases. It is known that >90% of deaths in breast cancer are related to the incidence of metastases and the complications that follow. Breast cancer is divided into several subtypes based on the expression of receptor genes in breast cancer tissue, namely Luminal A, Luminal B, HER 2 and Triple Negative Breast Cancer (TNBC). This study aims to determine the relationship between breast cancer subtypes and the incidence of metastases in Dr. M. Djamil Padang. Methods: This study used a retrospective case-control study to breast cancer patients with metastatic at Dr M Djamil Hospital, Padang from 2016-2021. The research subjects were 260 breast cancer patients who met the inclusion criteria. The study subjects were divided into 130 patients as the case group with metastases and 130 patients as the control group with no metastases. To determine the relationship between breast cancer subtypes and the incidence of metastases, the chi-square test was used. If the p value <0.05, it can be concluded that it is significant. Furthermore, analysis is continued to obtain an odds ratio (OR) in identifying risk opportunities with Cochran's and Mantle-Haenszel statistics common odds ratio estimate. The data were analysed using the Statistical Package for Social Sciences (SPSS) program. Result: Characteristics of the subjects in this study can be seen that there is a relationship between hormonal contraception, T and N status with the incidence of metastasis (p <0.05). Patients with metastases were more common with breast cancer subtypes luminal B (61.5%), HER2+ (21.5%), TNBC (14.6%) and luminal A (2.3%). The most common locations for breast cancer metastases were lung (48.5%), bone (26.2%), liver (19.2%), brain (5.4%) and other places (0.8%). There was a relationship between breast cancer subtypes and the incidence of metastasis (p<0.038). The highest risk of metastases was in patients with TNBC subtype with OR = 7.74 (95% CI 1.72-34.79). There was no relationship between breast cancer subtypes with metastatic location (p>0.05) and breast cancer subtypes TNBC had a risk (OR) of 9.60 (95% CI 1.96-47.14) times increasing the risk of metastases in brain. Conclusion: It can be concluded that there was a relationship between breast cancer subtypes and the incidence of metastasis

Sign in / Sign up

Export Citation Format

Share Document